Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This research study aims to determine what effects (good and bad) Durvalumab has on
participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing
chemotherapy and radiation. The study will also determine the logistic barriers to the quick
start of Durvalumab.